Search

Your search keyword '"Wildiers, Hans"' showing total 1,445 results
Start Over Author "Wildiers, Hans"
1,445 results on '"Wildiers, Hans"'

1. Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are not associated with distant metastases

Author

Wu, Qi, Hatse, Sigrid, Kenis, Cindy, Fernández-García, Juan, Altea-Manzano, Patricia, Billen, Jaak, Planque, Mélanie, Vandekeere, Anke, Lambrechts, Yentl, Richard, François, Punie, Kevin, Neven, Patrick, Smeets, Ann, Nevelsteen, Ines, Floris, Giuseppe, Desmedt, Christine, Gomes, Ana P., Fendt, Sarah-Maria, and Wildiers, Hans

Published
2024
Full Text
View/download PDF

4. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk.

Author

Gómez-Vecino, Aurora, Corchado-Cobos, Roberto, Blanco-Gómez, Adrián, García-Sancha, Natalia, Castillo-Lluva, Sonia, Martín-García, Ana, Mendiburu-Eliçabe, Marina, Prieto, Carlos, Ruiz-Pinto, Sara, Pita, Guillermo, Velasco-Ruiz, Alejandro, Patino-Alonso, Carmen, Galindo-Villardón, Purificación, Vera-Pedrosa, María, Jalife, José, Macías de Plasencia, Guillermo, Castellanos-Martín, Andrés, Sáez-Freire, María, Fraile-Martín, Susana, Rodrigues-Teixeira, Telmo, García-Macías, Carmen, Galvis-Jiménez, Julie, García-Sánchez, Asunción, Isidoro-García, María, Fuentes, Manuel, García-Cenador, María, García-Criado, Francisco, García-Hernández, Juan, Hernández-García, María, Cruz-Hernández, Juan, Rodríguez-Sánchez, César, García-Sancho, Alejandro, Pérez-López, Estefanía, Pérez-Martínez, Antonio, Gutiérrez-Larraya, Federico, Cartón, Antonio, García-Sáenz, José, Patiño-García, Ana, Martín, Miguel, Alonso-Gordoa, Teresa, Vulsteke, Christof, Croes, Lieselot, Hatse, Sigrid, Van Brussel, Thomas, Lambrechts, Diether, Wildiers, Hans, Chang, Hang, Holgado-Madruga, Marina, González-Neira, Anna, Sánchez, Pedro, Pérez Losada, Jesús, and Mao, Jian-Hua

Subjects
anthracyclines, cardiotoxicity, complex genetic disease, intermediate molecular phenotypes, quantitative trait loci, Female, Animals, Mice, Cardiotoxicity, Anthracyclines, Genetic Markers, Antibiotics, Antineoplastic, Neoplasms, Phenotype
Abstract

Cardiotoxicity due to anthracyclines (CDA) affects cancer patients, but we cannot predict who may suffer from this complication. CDA is a complex trait with a polygenic component that is mainly unidentified. We propose that levels of intermediate molecular phenotypes (IMPs) in the myocardium associated with histopathological damage could explain CDA susceptibility, so variants of genes encoding these IMPs could identify patients susceptible to this complication. Thus, a genetically heterogeneous cohort of mice (n = 165) generated by backcrossing were treated with doxorubicin and docetaxel. We quantified heart fibrosis using an Ariol slide scanner and intramyocardial levels of IMPs using multiplex bead arrays and QPCR. We identified quantitative trait loci linked to IMPs (ipQTLs) and cdaQTLs via linkage analysis. In three cancer patient cohorts, CDA was quantified using echocardiography or Cardiac Magnetic Resonance. CDA behaves as a complex trait in the mouse cohort. IMP levels in the myocardium were associated with CDA. ipQTLs integrated into genetic models with cdaQTLs account for more CDA phenotypic variation than that explained by cda-QTLs alone. Allelic forms of genes encoding IMPs associated with CDA in mice, including AKT1, MAPK14, MAPK8, STAT3, CAS3, and TP53, are genetic determinants of CDA in patients. Two genetic risk scores for pediatric patients (n = 71) and women with breast cancer (n = 420) were generated using machine-learning Least Absolute Shrinkage and Selection Operator (LASSO) regression. Thus, IMPs associated with heart damage identify genetic markers of CDA risk, thereby allowing more personalized patient management.

Published
2023

5. Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Author

Brandão, Mariana, Martins-Branco, Diogo, De Angelis, Claudia, Vuylsteke, Peter, Gelber, Richard D., Van Damme, Nancy, van Walle, Lien, Ferreira, Arlindo R., Lambertini, Matteo, Poggio, Francesca, Verhoeven, Didier, Barbeaux, Annelore, Duhoux, Francois P., Wildiers, Hans, Caballero, Carmela, Awada, Ahmad, Piccart-Gebhart, Martine, Punie, Kevin, and de Azambuja, Evandro

Published
2024
Full Text
View/download PDF

6. Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Author

Brandão, Mariana, Martins-Branco, Diogo, De Angelis, Claudia, Vuylsteke, Peter, Gelber, Richard D., Van Damme, Nancy, van Walle, Lien, Ferreira, Arlindo R., Lambertini, Matteo, Poggio, Francesca, Verhoeven, Didier, Barbeaux, Annelore, Duhoux, Francois P., Wildiers, Hans, Caballero, Carmela, Awada, Ahmad, Piccart-Gebhart, Martine, Punie, Kevin, and de Azambuja, Evandro

Published
2024
Full Text
View/download PDF

8. A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry

Author

Middha, Pooja, Wang, Xiaoliang, Behrens, Sabine, Bolla, Manjeet K., Wang, Qin, Dennis, Joe, Michailidou, Kyriaki, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Aronson, Kristan J., Auer, Paul L., Augustinsson, Annelie, Baert, Thaïs, Freeman, Laura E. Beane, Becher, Heiko, Beckmann, Matthias W., Benitez, Javier, Bojesen, Stig E., Brauch, Hiltrud, Brenner, Hermann, Brooks-Wilson, Angela, Campa, Daniele, Canzian, Federico, Carracedo, Angel, Castelao, Jose E., Chanock, Stephen J., Chenevix-Trench, Georgia, Cordina-Duverger, Emilie, Couch, Fergus J., Cox, Angela, Cross, Simon S., Czene, Kamila, Dossus, Laure, Dugué, Pierre-Antoine, Eliassen, A. Heather, Eriksson, Mikael, Evans, D. Gareth, Fasching, Peter A., Figueroa, Jonine D., Fletcher, Olivia, Flyger, Henrik, Gabrielson, Marike, Gago-Dominguez, Manuela, Giles, Graham G., González-Neira, Anna, Grassmann, Felix, Grundy, Anne, Guénel, Pascal, Haiman, Christopher A., Håkansson, Niclas, Hall, Per, Hamann, Ute, Hankinson, Susan E., Harkness, Elaine F., Holleczek, Bernd, Hoppe, Reiner, Hopper, John L., Houlston, Richard S., Howell, Anthony, Hunter, David J., Ingvar, Christian, Isaksson, Karolin, Jernström, Helena, John, Esther M., Jones, Michael E., Kaaks, Rudolf, Keeman, Renske, Kitahara, Cari M., Ko, Yon-Dschun, Koutros, Stella, Kurian, Allison W., Lacey, James V., Lambrechts, Diether, Larson, Nicole L., Larsson, Susanna, Le Marchand, Loic, Lejbkowicz, Flavio, Li, Shuai, Linet, Martha, Lissowska, Jolanta, Martinez, Maria Elena, Maurer, Tabea, Mulligan, Anna Marie, Mulot, Claire, Murphy, Rachel A., Newman, William G., Nielsen, Sune F., Nordestgaard, Børge G., Norman, Aaron, O’Brien, Katie M., Olson, Janet E., Patel, Alpa V., Prentice, Ross, Rees-Punia, Erika, Rennert, Gad, Rhenius, Valerie, Ruddy, Kathryn J., Sandler, Dale P., Scott, Christopher G., Shah, Mitul, Shu, Xiao-Ou, Smeets, Ann, Southey, Melissa C., Stone, Jennifer, Tamimi, Rulla M., Taylor, Jack A., Teras, Lauren R., Tomczyk, Katarzyna, Troester, Melissa A., Truong, Thérèse, Vachon, Celine M., Wang, Sophia S., Weinberg, Clarice R., Wildiers, Hans, Willett, Walter, Winham, Stacey J., Wolk, Alicja, Yang, Xiaohong R., Zamora, M. Pilar, Zheng, Wei, Ziogas, Argyrios, Dunning, Alison M., Pharoah, Paul D. P., García-Closas, Montserrat, Schmidt, Marjanka K., Kraft, Peter, Milne, Roger L., Lindström, Sara, Easton, Douglas F., and Chang-Claude, Jenny

Published
2023
Full Text
View/download PDF

9. Obesity-associated changes in molecular biology of primary breast cancer

Author

Nguyen, Ha-Linh, Geukens, Tatjana, Maetens, Marion, Aparicio, Samuel, Bassez, Ayse, Borg, Ake, Brock, Jane, Broeks, Annegien, Caldas, Carlos, Cardoso, Fatima, De Schepper, Maxim, Delorenzi, Mauro, Drukker, Caroline A., Glas, Annuska M., Green, Andrew R., Isnaldi, Edoardo, Eyfjörð, Jórunn, Khout, Hazem, Knappskog, Stian, Krishnamurthy, Savitri, Lakhani, Sunil R., Langerod, Anita, Martens, John W. M., McCart Reed, Amy E., Murphy, Leigh, Naulaerts, Stefan, Nik-Zainal, Serena, Nevelsteen, Ines, Neven, Patrick, Piccart, Martine, Poncet, Coralie, Punie, Kevin, Purdie, Colin, Rakha, Emad A., Richardson, Andrea, Rutgers, Emiel, Vincent-Salomon, Anne, Simpson, Peter T., Schmidt, Marjanka K., Sotiriou, Christos, Span, Paul N., Tan, Kiat Tee Benita, Thompson, Alastair, Tommasi, Stefania, Van Baelen, Karen, Van de Vijver, Marc, Van Laere, Steven, van’t Veer, Laura, Viale, Giuseppe, Viari, Alain, Vos, Hanne, Witteveen, Anke T., Wildiers, Hans, Floris, Giuseppe, Garg, Abhishek D., Smeets, Ann, Lambrechts, Diether, Biganzoli, Elia, Richard, François, and Desmedt, Christine

Published
2023
Full Text
View/download PDF

12. Study protocol for two stepped-wedge interventional trials evaluating the effects of holistic information technology-based patient-oriented management in older multimorbid patients with cancer: The GERONTE trials

Author

Hamaker, Marije E., Wildiers, Hans, Ardito, Vittoria, Arsandaux, Julie, Barthod-Malat, Aurore, Davies, Paul, Degol, Lien, Ferrara, Lucia, Fourrier, Celia, Kenis, Cindy, Kret, Marion, Lalet, Caroline, Pelissier, Simone Mathoulin, O'Hanlon, Shane, Rostoft, Siri, Seghers, Nelleke, Saillour-Glénisson, Florence, Staines, Anthony, Schwimmer, Christine, Thevenet, Vincent, Wallet, Cedric, and Soubeyran, Pierre

Published
2024
Full Text
View/download PDF

14. Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

Author

Rugo, Hope S, Kabos, Peter, Beck, J Thad, Jerusalem, Guy, Wildiers, Hans, Sevillano, Elena, Paz-Ares, Luis, Chisamore, Michael J, Chapman, Sonya C, Hossain, Anwar M, Chen, Yanyun, and Tolaney, Sara M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Patient Safety, Cancer, Clinical Trials and Supportive Activities, Genetics, Clinical Research, Breast Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Clinical sciences, Oncology and carcinogenesis, Epidemiology
Abstract

This nonrandomized, open-label, multi-cohort Phase 1b study (NCT02779751) investigated the safety and efficacy of abemaciclib plus pembrolizumab with/without anastrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) without prior CDK4 and 6 inhibitor exposure. Patients were divided into two cohorts: treatment naïve (cohort 1) and pretreated (cohort 2). Patients received abemaciclib plus pembrolizumab with (cohort 1) or without (cohort 2) anastrozole over 21-day cycles. The primary objective was safety, and secondary objectives included efficacy and pharmacokinetics (PK). Cohort 1/2 enrolled 26/28 patients, respectively. Neutropenia (30.8/28.6%), AST increase (34.6/17.9%), ALT increase (42.3/10.7%), and diarrhea (3.8/10.7%) were the most frequent grade ≥3 adverse events in cohort 1/2, respectively. A total of two deaths occurred, which investigators attributed to treatment-related adverse events (AEs), both in cohort 1. Higher rates of all grade and grade ≥3 interstitial lung disease (ILD)/pneumonitis were observed compared to previously reported with abemaciclib and pembrolizumab monotherapy. The PK profiles were consistent between cohorts and with previous monotherapy studies. In cohorts 1/2, the overall response rate and disease control rate were 23.1/28.6% and 84.6/82.1%, respectively. Median progression-free survival and overall survivals were 8.9 (95% CI: 3.9-11.1) and 26.3 months (95% CI: 20.0-31.0) for cohort 2; cohort 1 data are immature. Abemaciclib plus pembrolizumab demonstrated antitumor activity, but high rates of ILD/pneumonitis and severe transaminase elevations occurred with/without anastrozole compared to the previous reporting. Benefit/risk analysis does not support further evaluation of this combination in the treatment of HR+, HER2- MBC.

Published
2022

15. A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling

Author

Altea-Manzano, Patricia, Doglioni, Ginevra, Liu, Yawen, Cuadros, Alejandro M., Nolan, Emma, Fernández-García, Juan, Wu, Qi, Planque, Mélanie, Laue, Kathrin Julia, Cidre-Aranaz, Florencia, Liu, Xiao-Zheng, Marin-Bejar, Oskar, Van Elsen, Joke, Vermeire, Ines, Broekaert, Dorien, Demeyer, Sofie, Spotbeen, Xander, Idkowiak, Jakub, Montagne, Aurélie, Demicco, Margherita, Alkan, H. Furkan, Rabas, Nick, Riera-Domingo, Carla, Richard, François, Geukens, Tatjana, De Schepper, Maxim, Leduc, Sophia, Hatse, Sigrid, Lambrechts, Yentl, Kay, Emily Jane, Lilla, Sergio, Alekseenko, Alisa, Geldhof, Vincent, Boeckx, Bram, de la Calle Arregui, Celia, Floris, Giuseppe, Swinnen, Johannes V., Marine, Jean-Christophe, Lambrechts, Diether, Pelechano, Vicent, Mazzone, Massimiliano, Zanivan, Sara, Cools, Jan, Wildiers, Hans, Baud, Véronique, Grünewald, Thomas G. P., Ben-David, Uri, Desmedt, Christine, Malanchi, Ilaria, and Fendt, Sarah-Maria

Published
2023
Full Text
View/download PDF

18. Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast CancerBiomarker Analysis of the Phase III NALA Study in HER2+ MBC

Author

Saura, Cristina, Matito, Judit, Oliveira, Mafalda, Wildiers, Hans, Brufksy, Adam M, Waters, Simon H, Hurvitz, Sara A, Moy, Beverly, Kim, Sung-Bae, Gradishar, William J, Queiroz, Geraldo Silva, Cronemberger, Eduardo, Wallweber, Gerald J, Bebchuk, Judith, Keyvanjah, Kiana, Lalani, Alshad S, Bryce, Richard, Vivancos, Ana, Eli, Lisa D, and Delaloge, Suzette

Subjects
Breast Cancer, Cancer, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Breast Neoplasms, Capecitabine, Correlation of Data, Female, Humans, Lapatinib, Neoplasm Metastasis, Quinolines, Retreatment, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeNeratinib plus capecitabine (N+C) demonstrated significant progression-free survival (PFS) benefit in NALA (NCT01808573), a randomized phase III trial comparing N+C with lapatinib + capecitabine (L+C) in 621 patients with HER2-positive (HER2+) metastatic breast cancer (MBC) who had received ≥2 prior HER2-directed regimens in the metastatic setting. We evaluated correlations between exploratory biomarkers and PFS.Patients and methodsSomatic mutations were evaluated by next-generation sequencing on primary or metastatic samples. HER2 protein expression was evaluated by central IHC, H-score, and VeraTag/HERmark. p95 expression (truncated HER2) was measured by VeraTag. HRs were estimated using unstratified Cox proportional hazards models.ResultsFour hundred and twenty samples had successful sequencing: 34.0% had PIK3CA mutations and 5.5% had HER2 (ERBB2) mutations. In the combined patient populations, PIK3CA mutations trended toward shorter PFS [wild-type vs. mutant, HR = 0.81; 95% confidence interval (CI), 0.64-1.03], whereas HER2 mutations trended toward longer PFS [HR = 1.69 (95% CI, 0.97-3.29)]. Higher HER2 protein expression was associated with longer PFS [IHC 3+ vs. 2+, HR = 0.67 (0.54-0.82); H-score ≥240 versus

Published
2021

20. Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program

Author

Geukens, Tatjana, De Schepper, Maxim, Van Den Bogaert, Wouter, Van Baelen, Karen, Maetens, Marion, Pabba, Anirudh, Mahdami, Amena, Leduc, Sophia, Isnaldi, Edoardo, Nguyen, Ha-Linh, Bachir, Imane, Hajipirloo, Maysam, Zels, Gitte, Van Cauwenberge, Josephine, Borremans, Kristien, Vandecaveye, Vincent, Weynand, Birgit, Vermeulen, Peter, Leucci, Eleonora, Baietti, Maria Francesca, Sflomos, George, Battista, Laura, Brisken, Cathrin, Derksen, Patrick W. B., Koorman, Thijs, Visser, Daan, Scheele, Colinda L. G. J., Thommen, Daniela S., Hatse, Sigrid, Fendt, Sarah-Maria, Vanderheyden, Evy, Van Brussel, Thomas, Schepers, Rogier, Boeckx, Bram, Lambrechts, Diether, Marano, Giuseppe, Biganzoli, Elia, Smeets, Ann, Nevelsteen, Ines, Punie, Kevin, Neven, Patrick, Wildiers, Hans, Richard, François, Floris, Giuseppe, and Desmedt, Christine

Published
2024
Full Text
View/download PDF

21. Reporting on invasive lobular breast cancer in clinical trials: a systematic review

Author

Van Baelen, Karen, Van Cauwenberge, Josephine, Maetens, Marion, Beck, Gabriela, Camden, Ann, Chase, Megan-Claire, Fraser, Valerie, Freeney, Siobhan, Hutcheson, Laurie, Levine, Julia K., Lien, Tone, Terveer, Rian, Turner, Claire, Senkus, Elzbieta, Jankowitz, Rachel C., Vandecaveye, Vincent, Floris, Giuseppe, Neven, Patrick, Wildiers, Hans, Sawyer, Elinor, Vincent-Salomon, Anne, Derksen, Patrick W. B., and Desmedt, Christine

Published
2024
Full Text
View/download PDF

22. Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab

Author

Debien, Veronique, Marta, Guilherme Nader, Agostinetto, Elisa, Sirico, Marianna, Jacobs, Flavia, Molinelli, Chiara, Moreau, Michel, Paesmans, Marianne, De Giorgi, Ugo, Santoro, Armando, Taylor, Donatienne, Duhoux, François P., Botticelli, Andrea, Barchiesi, Giacomo, Speranza, Iolanda, Lambertini, Matteo, Wildiers, Hans, Azambuja, Evandro de, and Piccart, Martine

Published
2023
Full Text
View/download PDF

23. Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer

Author

Van Baelen, Karen, Nguyen, Ha-Linh, Hamy-Petit, Anne-Sophie, Richard, François, Karsten, Maria Margarete, Nader Marta, Guilherme, Vermeulen, Peter, Toussaint, Aullene, Reyal, Fabien, Vincent-Salomon, Anne, Dirix, Luc, Dordevic, Adam David, de Azambuja, Evandro, Larsimont, Denis, Amato, Ottavia, Maetens, Marion, De Schepper, Maxim, Geukens, Tatjana, Han, Sileny N., Baert, Thaïs, Punie, Kevin, Wildiers, Hans, Smeets, Ann, Nevelsteen, Ines, Floris, Giuseppe, Biganzoli, Elia, Neven, Patrick, and Desmedt, Christine

Published
2023
Full Text
View/download PDF

25. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).

Author

Curigliano, Giuseppe, primary, Hu, Xichun, additional, Dent, Rebecca Alexandra, additional, Yonemori, Kan, additional, Barrios, Carlos H., additional, O'Shaughnessy, Joyce, additional, Wildiers, Hans, additional, Zhang, Qingyuan, additional, Im, Seock-Ah, additional, Saura, Cristina, additional, Biganzoli, Laura, additional, Sohn, Joohyuk, additional, Levy, Christelle, additional, Jacot, William, additional, Begbie, Natasha, additional, Ke, Jun, additional, Patel, Gargi Surendra, additional, and Bardia, Aditya, additional

Published
2024
Full Text
View/download PDF

26. Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial.

Author

Jhaveri, Komal L., primary, Hurvitz, Sara A., additional, Brufsky, Adam, additional, Bose, Ron, additional, de Miguel, Maria J., additional, Evron, Ella, additional, Unni, Nisha, additional, Reid, Sonya A., additional, Quinn, David I., additional, Mahalingam, Devalingam, additional, Saura, Cristina, additional, García-Sáenz, Jose A., additional, Martinez-Bueno, Alejandro, additional, Guerrero, Angel, additional, De La Fouchardiere, Christelle, additional, Wildiers, Hans, additional, Bischof, Georg Friedrich, additional, Bebchuk, Judith D., additional, Eli, Lisa DeFazio, additional, and Solit, David B., additional

Published
2024
Full Text
View/download PDF

28. Long-term health-care utilisation in older patients with cancer and the association with the Geriatric 8 screening tool: a retrospective analysis using linked clinical and population-based data in Belgium

Author

Depoorter, Victoria, Vanschoenbeek, Katrijn, Decoster, Lore, Silversmit, Geert, Debruyne, Philip R, De Groof, Inge, Bron, Dominique, Cornélis, Frank, Luce, Sylvie, Focan, Christian, Verschaeve, Vincent, Debugne, Gwenaëlle, Langenaeken, Christine, Van Den Bulck, Heidi, Goeminne, Jean-Charles, Teurfs, Wesley, Jerusalem, Guy, Schrijvers, Dirk, Petit, Bénédicte, Rasschaert, Marika, Praet, Jean-Philippe, Vandenborre, Katherine, Milisen, Koen, Flamaing, Johan, Kenis, Cindy, Verdoodt, Freija, and Wildiers, Hans

Published
2023
Full Text
View/download PDF

29. Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer

Author

Geukens, Tatjana, De Schepper, Maxim, Richard, François, Maetens, Marion, Van Baelen, Karen, Mahdami, Amena, Nguyen, Ha-Linh, Isnaldi, Edoardo, Leduc, Sophia, Pabba, Anirudh, Zels, Gitte, Mertens, Freya, Vander Borght, Sara, Smeets, Ann, Nevelsteen, Ines, Punie, Kevin, Neven, Patrick, Wildiers, Hans, Van Den Bogaert, Wouter, Floris, Giuseppe, and Desmedt, Christine

Published
2023
Full Text
View/download PDF

31. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

Author

Rugo, Hope S, Dieras, Veronique, Cortes, Javier, Patt, Debra, Wildiers, Hans, O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A, Carter, Gebra Cuyun, Sheffield, Kristin M, Li, Li, Andre, Valerie AM, Li, Xiaohong I, Frenzel, Martin, Huang, Yu-Jing, Dickler, Maura N, and Tolaney, Sara M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Breast Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Capecitabine, Female, Humans, Proportional Hazards Models, Receptor, ErbB-2, Vinorelbine, Abemaciclib, Electronic health records, Metastatic breast cancer, Overall survival, Real-world evidence, Retrospective study, Single-arm trial, Real-world control arm, Receptor, erbB-2, Clinical Sciences, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeIn MONARCH 1 (NCT02102490), single-agent abemaciclib demonstrated promising efficacy activity and tolerability in a population of heavily pretreated women with refractory HR+, HER2- metastatic breast cancer (MBC). To help interpret these results and put in clinical context, we compared overall survival (OS) and duration of therapy (DoT) between MONARCH 1 and a real-world single-agent chemotherapy cohort.MethodsThe real-world chemotherapy cohort was created from a Flatiron Health electronic health records-derived database based on key eligibility criteria from MONARCH 1. The chemotherapies included in the cohort were single-agent capecitabine, gemcitabine, eribulin, or vinorelbine. Results were adjusted for baseline demographics and clinical differences using Mahalanobis distance matching (primary analysis) and entropy balancing (sensitivity analysis). OS and DoT were analyzed using the Kaplan-Meier method and Cox proportional hazards regression.ResultsA real-world single-agent chemotherapy cohort (n = 281) with eligibility criteria similar to the MONARCH 1 population (n = 132) was identified. The MONARCH 1 (n = 108) cohort was matched to the real-world chemotherapy cohort (n = 108). Median OS was 22.3 months in the abemaciclib arm versus 13.6 months in the matched real-world chemotherapy cohort with an estimated hazard ratio (HR) of 0.54. The median DoT was 4.1 months in MONARCH 1 compared to 2.9 months in the real-world chemotherapy cohort with HR of 0.76.ConclusionsThis study demonstrates an approach to create a real-world chemotherapy cohort suitable to serve as a comparator for trial data. These exploratory results suggest a survival advantage and place the benefit of abemaciclib monotherapy in clinical context.

Published
2020

32. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.

Author

Rugo, Hope S, Dieras, Veronique, Cortes, Javier, Patt, Debra, Wildiers, Hans, O'Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A, Carter, Gebra Cuyun, Sheffield, Kristin M, Li, Li, Andre, Valerie AM, Li, Xiaohong I, Frenzel, Martin, Huang, Yu-Jing, Dickler, Maura N, and Tolaney, Sara M

Subjects
Abemaciclib, Electronic health records, Metastatic breast cancer, Overall survival, Real-world control arm, Real-world evidence, Retrospective study, Single-arm trial, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeIn MONARCH 1 (NCT02102490), single-agent abemaciclib demonstrated promising efficacy activity and tolerability in a population of heavily pretreated women with refractory HR+, HER2- metastatic breast cancer (MBC). To help interpret these results and put in clinical context, we compared overall survival (OS) and duration of therapy (DoT) between MONARCH 1 and a real-world single-agent chemotherapy cohort.MethodsThe real-world chemotherapy cohort was created from a Flatiron Health electronic health records-derived database based on key eligibility criteria from MONARCH 1. The chemotherapies included in the cohort were single-agent capecitabine, gemcitabine, eribulin, or vinorelbine. Results were adjusted for baseline demographics and clinical differences using Mahalanobis distance matching (primary analysis) and entropy balancing (sensitivity analysis). OS and DoT were analyzed using the Kaplan-Meier method and Cox proportional hazards regression.ResultsA real-world single-agent chemotherapy cohort (n = 281) with eligibility criteria similar to the MONARCH 1 population (n = 132) was identified. The MONARCH 1 (n = 108) cohort was matched to the real-world chemotherapy cohort (n = 108). Median OS was 22.3 months in the abemaciclib arm versus 13.6 months in the matched real-world chemotherapy cohort with an estimated hazard ratio (HR) of 0.54. The median DoT was 4.1 months in MONARCH 1 compared to 2.9 months in the real-world chemotherapy cohort with HR of 0.76.ConclusionsThis study demonstrates an approach to create a real-world chemotherapy cohort suitable to serve as a comparator for trial data. These exploratory results suggest a survival advantage and place the benefit of abemaciclib monotherapy in clinical context.

Published
2020

33. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Author

Saura, Cristina, Oliveira, Mafalda, Feng, Yin-Hsun, Dai, Ming-Shen, Chen, Shang-Wen, Hurvitz, Sara A, Kim, Sung-Bae, Moy, Beverly, Delaloge, Suzette, Gradishar, William, Masuda, Norikazu, Palacova, Marketa, Trudeau, Maureen E, Mattson, Johanna, Yap, Yoon Sim, Hou, Ming-Feng, De Laurentiis, Michelino, Yeh, Yu-Min, Chang, Hong-Tai, Yau, Thomas, Wildiers, Hans, Haley, Barbara, Fagnani, Daniele, Lu, Yen-Shen, Crown, John, Lin, Johnson, Takahashi, Masato, Takano, Toshimi, Yamaguchi, Miki, Fujii, Takaaki, Yao, Bin, Bebchuk, Judith, Keyvanjah, Kiana, Bryce, Richard, and Brufsky, Adam

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Prevention, Clinical Research, Cancer, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Breast Neoplasms, Male, Capecitabine, Diarrhea, Female, Humans, Kaplan-Meier Estimate, Lapatinib, Male, Middle Aged, Nausea, Progression-Free Survival, Quality of Life, Quinolines, Receptor, ErbB-2, Retreatment, Survival Rate, NALA Investigators, Receptor, erbB-2, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeNALA (ClinicalTrials.gov identifier: NCT01808573) is a randomized, active-controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), plus capecitabine (N+C) against lapatinib, a reversible dual TKI, plus capecitabine (L+C) in patients with centrally confirmed HER2-positive, metastatic breast cancer (MBC) with ≥ 2 previous HER2-directed MBC regimens.MethodsPatients, including those with stable, asymptomatic CNS disease, were randomly assigned 1:1 to neratinib (240 mg once every day) plus capecitabine (750 mg/m2 twice a day 14 d/21 d) with loperamide prophylaxis, or to lapatinib (1,250 mg once every day) plus capecitabine (1,000 mg/m2 twice a day 14 d/21 d). Coprimary end points were centrally confirmed progression-free survival (PFS) and overall survival (OS). NALA was considered positive if either primary end point was met (α split between end points). Secondary end points were time to CNS disease intervention, investigator-assessed PFS, objective response rate (ORR), duration of response (DoR), clinical benefit rate, safety, and health-related quality of life (HRQoL).ResultsA total of 621 patients from 28 countries were randomly assigned (N+C, n = 307; L+C, n = 314). Centrally reviewed PFS was improved with N+C (hazard ratio [HR], 0.76; 95% CI, 0.63 to 0.93; stratified log-rank P = .0059). The OS HR was 0.88 (95% CI, 0.72 to 1.07; P = .2098). Fewer interventions for CNS disease occurred with N+C versus L+C (cumulative incidence, 22.8% v 29.2%; P = .043). ORRs were N+C 32.8% (95% CI, 27.1 to 38.9) and L+C 26.7% (95% CI, 21.5 to 32.4; P = .1201); median DoR was 8.5 versus 5.6 months, respectively (HR, 0.50; 95% CI, 0.33 to 0.74; P = .0004). The most common all-grade adverse events were diarrhea (N+C 83% v L+C 66%) and nausea (53% v 42%). Discontinuation rates and HRQoL were similar between groups.ConclusionN+C significantly improved PFS and time to intervention for CNS disease versus L+C. No new N+C safety signals were observed.

Published
2020

34. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Author

Braybrooke, Jeremy, Bradley, Rosie, Gray, Richard, Hills, Robert K, Pan, Hongchao, Peto, Richard, Dodwell, David, McGale, Paul, Taylor, Carolyn, Aihara, Tomohiko, Anderson, Stewart, Blum, Joanne, Cardoso, Fatima, Chen, Xiaosong, Crown, John P, Ejlertsen, Bent, Friedl, Thomas W P, Harbeck, Nadia, Janni, Wolfgang, Jensen, Maj-Britt, Mamounas, Eleftherios, Narui, Kazutaka, Nitz, Ulrike, Norton, Larry, O'Shaughnessy, Joyce, Piccart, Martine, Robert, Nicholas, Shao, Zhi-Ming, Slamon, Dennis, Sparano, Joseph, Watanabe, Toru, Yothers, Greg, Yu, Ke-Da, Berry, Richard, Boddington, Clare, Clarke, Mike, Davies, Christina, Davies, Lucy, Duane, Fran, Evans, Vaughan, Gay, Jo, Gettins, Lucy, Godwin, Jon, James, Sam, Lui, Hui, Lui, Zulian, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Read, Simon, Straiton, Ewan, Buzdar, Aman, Suman, Vera J, Hunt, Kelly K, Leonard, Robert C F, Mansi, Janine, Delbaldo, Catherine, Piedbois, Pascal, Quinaux, Emmanuel, Fesl, Christian, Gnant, Michael, Sölkner, Lidija, Steger, Guenther, Eikesdal, Hans Petter, Lønning, Per Eystein, Bee, Valerie, Fung, Helena, Mackey, John, Martin, Miguel, Press, Michael, De Azambuja, Evandro, Gelber, Richard, Regan, Meredith, Di Leo, Angelo, Van Dooren, Veerle, Nogaret, Jean Marie, Bartlett, John, Chen, Bingshu E, Gelmon, Karen, Goss, Paul E, Levine, Mark N, Parulekar, Wendy, Pritchard, Kathleen I, Shepherd, Lois, Berry, Donald, Cirrincione, Constance, Shulman, Lawrence N, Winer, Eric, Gelman, Rebecca S, Harris, Jay R, Henderson, Craig, Shapiro, Charles L, Christiansen, Peer, Ewertz, Marianne, Mouridsen, Henning T, Van Leeuwen, Elise, Linn, Sabine, Van Rossum, Annelot G J, Van Tinteren, Harm, Van Werkhoven, Erik, Goldstein, Lori, Gray, Robert, Eiermann, Wolfgang, Gianni, Luca, Valagussa, Pinuccia, Bogaerts, Jan, Bonnefoi, Herve, Poncet, Coralie, Huovinen, Riikka, Joensuu, Heikki, Bonneterre, Jacques, Fargeot, Pierre, Fumoleau, Pierre, Kerbrat, Pierre, Luporsi, Elisabeth, Namer, Moïse, Carrasco, Eva M, Segui, Miguel Angel, Meisner, Christoph, Loibl, Sibylle, Nekljudova, Valentina, Thomssen, Christoph, Von Minckwitz, Gunter, Kümmel, Sherko, Lopez, Massimo, Vici, Patrizia, Fountzilas, George, Koliou, Georgia, Mavroudis, Dimitrios, Saloustros, Emmanouil, Brain, Etienne, Delaloge, Suzette, Michiels, Stefan, Mathoulin-Pelissier, Simone, Bines, Jose, Sarmento, Roberta M B, Bonadonna, Gianni, Brambilla, Cristina, Rossi, Anna, Bliss, Judith, Coombes, Raoul Charles, Kilburn, Lucy, Marty, Michel, Amadori, Dino, Boccardo, Francesco, Nanni, Oriana, Rubagotti, Alessandra, Scarpi, Emanuela, Masuda, Norikazu, Toi, Masakazu, Ueno, Takayuki, Ishikawa, Takashi, Matsumoto, Koji, Takao, Shintaro, Sommer, Harald, Foroglou, Pericles, Giokas, George, Kondylis, D, Lissaios, Byron, Reinisch, Mattea, Lee, Keun Seok, Nam, Byung-Ho, Ro, Jung Sil, De Matteis, Andrea, Perrone, Francesco, Tang, Gong, Wolmark, Norman, Hozumi, Yasuo, Nomura, Yasuo, Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, De Mastro, Lucia, Venturini, Macro, Delozier, Thierry, Lemonnier, Jerome, Martin, Anne-Laure, Roché, Henri, Spielmann, Marc, Chen, Xiasong, Shen, Kunwei, Albain, Kathy, Barlow, William, Budd, George T, Gralow, Julie, Hayes, Dan, Bartlett-Lee, Peter, Ellis, Paul, Bianco, Angelo Raffaele, De Laurentiis, Michelino, De Placido, Sabino, Wildiers, Hans, Hsu, Limin, Eremin, Oleg, Walker, Leslie G, Ahlgren, Johan, Blomqvist, Carl, Holmberg, Lars, Lindman, Henrik, Asmar, Lina, Jones, Stephen E, Gluz, Oleg, Liedtke, Cornelia, Arriagada, Rodrigo, Bergsten-Nordström, Elizabeth, Carey, Lisa, Coleman, Robert, Cuzick, Jack, Davidson, Nancy, Dignam, James, Dowsett, Mitch, Francis, Prudence A, Goetz, Matthew P, Goodwin, Pam, Halpin-Murphy, Pat, Hill, Catherine, Jagsi, Reshma, Mukai, Hirofumi, Ohashi, Yasuo, Pierce, Lori, Poortmans, Philip, Raina, Vinod, Rea, Daniel, Robertson, John, Rutgers, Emiel, Salgado, Roberto, Spanic, Tanja, Tutt, Andrew, Viale, Giuseppe, Wang, Xiang, Whelan, Tim, Wilcken, Nicholas, Cameron, David, Bergh, Jonas, and Swain, Sandra M

Published
2023
Full Text
View/download PDF

35. Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes

Author

Depoorter, Victoria, Vanschoenbeek, Katrijn, Decoster, Lore, De Schutter, Harlinde, Debruyne, Philip R., De Groof, Inge, Bron, Dominique, Cornélis, Frank, Luce, Sylvie, Focan, Christian, Verschaeve, Vincent, Debugne, Gwenaëlle, Langenaeken, Christine, Van Den Bulck, Heidi, Goeminne, Jean-Charles, Teurfs, Wesley, Jerusalem, Guy, Schrijvers, Dirk, Petit, Bénédicte, Rasschaert, Marika, Praet, Jean-Philippe, Vandenborre, Katherine, Milisen, Koen, Flamaing, Johan, Kenis, Cindy, Verdoodt, Freija, and Wildiers, Hans

Published
2023
Full Text
View/download PDF

36. Oncological care organisation during COVID-19 outbreak.

Author

Onesti, Concetta Elisa, Rugo, Hope S, Generali, Daniele, Peeters, Marc, Zaman, Khalil, Wildiers, Hans, Harbeck, Nadia, Martin, Miguel, Cristofanilli, Massimo, Cortes, Javier, Tjan-Heijnen, Vivianne, Hurvitz, Sara A, Berchem, Guy, Tagliamento, Marco, Campone, Mario, Bartsch, Rupert, De Placido, Sabino, Puglisi, Fabio, Rottey, Sylvie, Müller, Volkmar, Ruhstaller, Thomas, Machiels, Jean-Pascal, Conte, PierFranco, Awada, Ahmad, and Jerusalem, Guy

Subjects
Humans, Pneumonia, Viral, Coronavirus Infections, Neoplasms, Health Care Surveys, Medical Oncology, Disinfection, Visitors to Patients, Cancer Care Facilities, Triage, Delivery of Health Care, United States, Europe, Pandemics, Personal Protective Equipment, Betacoronavirus, COVID-19, SARS-CoV-2, oncological care
Abstract

BackgroundCOVID-19 appeared in late 2019, causing a pandemic spread. This led to a reorganisation of oncology care in order to reduce the risk of spreading infection between patients and healthcare staff. Here we analysed measures taken in major oncological units in Europe and the USA.MethodsA 46-item survey was sent by email to representatives of 30 oncological centres in 12 of the most affected countries. The survey inquired about preventive measures established to reduce virus spread, patient education and processes employed for risk reduction in each oncological unit.ResultsInvestigators from 21 centres in 10 countries answered the survey between 10 April and 6 May 2020. A triage for patients with cancer before hospital or clinic visits was conducted by 90.5% of centres before consultations, 95.2% before day care admissions and in 100% of the cases before overnight hospitalisation by means of phone calls, interactive online platforms, swab test and/or chest CT scan. Permission for caregivers to attend clinic visits was limited in many centres, with some exceptions (ie, for non-autonomous patients, in the case of a new diagnosis, when bad news was expected and for terminally ill patients). With a variable delay period, the use of personal protective equipment was unanimously mandatory, and in many centres, only targeted clinical and instrumental examinations were performed. Telemedicine was implemented in 76.2% of the centres. Separated pathways for COVID-19-positive and COVID-19-negative patients were organised, with separate inpatient units and day care areas. Self-isolation was required for COVID-19-positive or symptomatic staff, while return to work policies required a negative swab test in 76.2% of the centres.ConclusionMany pragmatic measures have been quickly implemented to deal with the health emergency linked to COVID-19, although the relative efficacy of each intervention should be further analysed in large observational studies.

Published
2020

37. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

Author

Hurvitz, Sara A, Martin, Miguel, Jung, Kyung Hae, Huang, Chiun-Sheng, Harbeck, Nadia, Valero, Vicente, Stroyakovskiy, Daniil, Wildiers, Hans, Campone, Mario, Boileau, Jean-François, Fasching, Peter A, Afenjar, Karen, Spera, Gonzalo, Lopez-Valverde, Vanesa, Song, Chunyan, Trask, Peter, Boulet, Thomas, Sparano, Joseph A, Symmans, W Fraser, Thompson, Alastair M, and Slamon, Dennis

Subjects
Clinical Trials and Supportive Activities, Patient Safety, Breast Cancer, Cancer, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Carboplatin, Chemotherapy, Adjuvant, Disease-Free Survival, Docetaxel, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoadjuvant Therapy, Receptor, ErbB-2, Trastuzumab, Receptor, erbB-2, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the treatment human epidermal growth factor receptor 2-positive stage II to III breast cancer. T-DM1+P led to a lower pathologic complete response rate (44.4% v 55.7%; P = .016), but fewer grade 3 or greater and serious adverse events (AEs). Here, we present 3-year outcomes from KRISTINE.MethodsPatients were randomly assigned to neoadjuvant T-DM1+P or TCH+P every 3 weeks for six cycles. Patients who received T-DM1+P continued adjuvant T-DM1+P, and patients who received TCH+P received adjuvant trastuzumab plus pertuzumab. Secondary end points included event-free survival (EFS), overall survival, patient-reported outcomes (measured from random assignment), and invasive disease-free survival (IDFS; measured from surgery).ResultsOf patients, 444 were randomly assigned (T-DM1+P, n = 223; TCH+P, n = 221). Median follow-up was 37 months. Risk of an EFS event was higher with TDM-1+P (hazard ratio [HR], 2.61 [95% CI, 1.36 to 4.98]) with more locoregional progression events before surgery (15 [6.7%] v 0). Risk of an IDFS event after surgery was similar between arms (HR, 1.11 [95% CI, 0.52 to 2.40]). Pathologic complete response was associated with a reduced risk of an IDFS event (HR, 0.24 [95% CI, 0.09 to 0.60]) regardless of treatment arm. Overall, grade 3 or greater AEs (31.8% v 67.7%) were less common with T-DM1+P. During adjuvant treatment, grade 3 or greater AEs (24.5% v 9.9%) and AEs leading to treatment discontinuation (18.4% v 3.8%) were more common with T-DM1+P. Patient-reported outcomes favored T-DM1+P during neoadjuvant treatment and were similar to trastuzumab plus pertuzumab during adjuvant treatment.ConclusionCompared with TCH+P, T-DM1+P resulted in a higher risk of an EFS event owing to locoregional progression events before surgery, a similar risk of an IDFS event, fewer grade 3 or greater AEs during neoadjuvant treatment, and more AEs leading to treatment discontinuation during adjuvant treatment.

Published
2019

38. Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer

Author

Guarneri, Valentina, primary, Passos Coelho, José Luís, additional, Duhoux, Francois P, additional, Egle, Daniel, additional, García-Sáenz, José Ángel, additional, Penault-Llorca, Frédérique, additional, Selander, Katri, additional, Wildiers, Hans, additional, Zaman, Khalil, additional, Laeis, Petra, additional, Lucerna, Markus, additional, and Pierga, Jean-Yves, additional

Published
2024
Full Text
View/download PDF

39. Metastases of primary mixed no-special type and lobular breast cancer display an exclusive lobular histology

Author

Zels, Gitte, primary, Van Baelen, Karen, additional, De Schepper, Maxim, additional, Borremans, Kristien, additional, Geukens, Tatjana, additional, Isnaldi, Edoardo, additional, Izci, Hava, additional, Leduc, Sophia, additional, Mahdami, Amena, additional, Maetens, Marion, additional, Nguyen, Ha Linh, additional, Pabba, Anirudh, additional, Richard, François, additional, Van Cauwenberge, Josephine, additional, Smeets, Ann, additional, Nevelsteen, Ines, additional, Neven, Patrick, additional, Wildiers, Hans, additional, Van Den Bogaert, Wouter, additional, Floris, Giuseppe, additional, and Desmedt, Christine, additional

Published
2024
Full Text
View/download PDF

40. Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast

Author

Geldhof, Vincent, de Rooij, Laura P. M. H., Sokol, Liliana, Amersfoort, Jacob, De Schepper, Maxim, Rohlenova, Katerina, Hoste, Griet, Vanderstichele, Adriaan, Delsupehe, Anne-Marie, Isnaldi, Edoardo, Dai, Naima, Taverna, Federico, Khan, Shawez, Truong, Anh-Co K., Teuwen, Laure-Anne, Richard, François, Treps, Lucas, Smeets, Ann, Nevelsteen, Ines, Weynand, Birgit, Vinckier, Stefan, Schoonjans, Luc, Kalucka, Joanna, Desmedt, Christine, Neven, Patrick, Mazzone, Massimiliano, Floris, Giuseppe, Punie, Kevin, Dewerchin, Mieke, Eelen, Guy, Wildiers, Hans, Li, Xuri, Luo, Yonglun, and Carmeliet, Peter

Published
2022
Full Text
View/download PDF

41. Incidence of falls and fall-related injuries and their predictive factors in frail older persons with cancer: a multicenter study

Author

Kenis, Cindy, Decoster, Lore, Flamaing, Johan, Debruyne, Philip R., De Groof, Inge, Focan, Christian, Cornélis, Frank, Verschaeve, Vincent, Bachmann, Christian, Bron, Dominique, Van den Bulck, Heidi, Schrijvers, Dirk, Langenaeken, Christine, Specenier, Pol, Jerusalem, Guy, Praet, Jean-Philippe, De Cock, Jessie, Lobelle, Jean-Pierre, Wildiers, Hans, and Milisen, Koen

Published
2022
Full Text
View/download PDF

43. Functional status in older patients with cancer and a frailty risk profile: A multicenter observational study

Author

Meert, Glen, Kenis, Cindy, Milisen, Koen, Debruyne, Philip R., De Groof, Inge, Focan, Christian, Cornélis, Frank, Verschaeve, Vincent, Bachmann, Christian, Bron, Dominique, Den Bulck, Heidi Van, Schrijvers, Dirk, Langenaeken, Christine, Specenier, Pol, Jerusalem, Guy, Praet, Jean-Philippe, Lobelle, Jean-Pierre, Flamaing, Johan, Wildiers, Hans, and Decoster, Lore

Published
2022
Full Text
View/download PDF

46. Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial

Author

Dal Lago, Lissandra, Uwimana, Aimé Lambert, Coens, Corneel, Vuylsteke, Peter, Curigliano, Giuseppe, Brouwers, Barbara, Jagiello-Gruszfeld, Agnieszka, Altintas, Sevilay, Tryfonidis, Konstantinos, Poncet, Coralie, Bottomley, Andrew, Sousa, Berta, Brain, Etienne, and Wildiers, Hans

Published
2022
Full Text
View/download PDF

49. Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

Author

Ghoussaini, Maya, Edwards, Stacey L, Michailidou, Kyriaki, Nord, Silje, Cowper-Sal Lari, Richard, Desai, Kinjal, Kar, Siddhartha, Hillman, Kristine M, Kaufmann, Susanne, Glubb, Dylan M, Beesley, Jonathan, Dennis, Joe, Bolla, Manjeet K, Wang, Qin, Dicks, Ed, Guo, Qi, Schmidt, Marjanka K, Shah, Mitul, Luben, Robert, Brown, Judith, Czene, Kamila, Darabi, Hatef, Eriksson, Mikael, Klevebring, Daniel, Bojesen, Stig E, Nordestgaard, Børge G, Nielsen, Sune F, Flyger, Henrik, Lambrechts, Diether, Thienpont, Bernard, Neven, Patrick, Wildiers, Hans, Broeks, Annegien, Van't Veer, Laura J, Rutgers, Emiel J Th, Couch, Fergus J, Olson, Janet E, Hallberg, Emily, Vachon, Celine, Chang-Claude, Jenny, Rudolph, Anja, Seibold, Petra, Flesch-Janys, Dieter, Peto, Julian, Dos-Santos-Silva, Isabel, Gibson, Lorna, Nevanlinna, Heli, Muranen, Taru A, Aittomäki, Kristiina, Blomqvist, Carl, Hall, Per, Li, Jingmei, Liu, Jianjun, Humphreys, Keith, Kang, Daehee, Choi, Ji-Yeob, Park, Sue K, Noh, Dong-Young, Matsuo, Keitaro, Ito, Hidemi, Iwata, Hiroji, Yatabe, Yasushi, Guénel, Pascal, Truong, Thérèse, Menegaux, Florence, Sanchez, Marie, Burwinkel, Barbara, Marme, Frederik, Schneeweiss, Andreas, Sohn, Christof, Wu, Anna H, Tseng, Chiu-Chen, Van Den Berg, David, Stram, Daniel O, Benitez, Javier, Pilar Zamora, M, Perez, Jose Ignacio Arias, Menéndez, Primitiva, Shu, Xiao-Ou, Lu, Wei, Gao, Yu-Tang, Cai, Qiuyin, Cox, Angela, Cross, Simon S, Reed, Malcolm WR, Andrulis, Irene L, Knight, Julia A, Glendon, Gord, Tchatchou, Sandrine, Sawyer, Elinor J, Tomlinson, Ian, Kerin, Michael J, Miller, Nicola, Haiman, Christopher A, Henderson, Brian E, Schumacher, Fredrick, Le Marchand, Loic, Lindblom, Annika, Margolin, Sara, and Teo, Soo Hwang

Abstract

This corrects the article DOI: 10.1038/ncomms5999.

Published
2018

50. Correction: Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation

Author

Ghoussaini, Maya, Edwards, Stacey L, Michailidou, Kyriaki, Nord, Silje, Cowper-Sal·lari, Richard, Desai, Kinjal, Kar, Siddhartha, Hillman, Kristine M, Kaufmann, Susanne, Glubb, Dylan M, Beesley, Jonathan, Dennis, Joe, Bolla, Manjeet K, Wang, Qin, Dicks, Ed, Guo, Qi, Schmidt, Marjanka K, Shah, Mitul, Luben, Robert, Brown, Judith, Czene, Kamila, Darabi, Hatef, Eriksson, Mikael, Klevebring, Daniel, Bojesen, Stig E, Nordestgaard, Børge G, Nielsen, Sune F, Flyger, Henrik, Lambrechts, Diether, Thienpont, Bernard, Neven, Patrick, Wildiers, Hans, Broeks, Annegien, Van’t Veer, Laura J, Rutgers, Emiel J Th, Couch, Fergus J, Olson, Janet E, Hallberg, Emily, Vachon, Celine, Chang-Claude, Jenny, Rudolph, Anja, Seibold, Petra, Flesch-Janys, Dieter, Peto, Julian, dos-Santos-Silva, Isabel, Gibson, Lorna, Nevanlinna, Heli, Muranen, Taru A, Aittomäki, Kristiina, Blomqvist, Carl, Hall, Per, Li, Jingmei, Liu, Jianjun, Humphreys, Keith, Kang, Daehee, Choi, Ji-Yeob, Park, Sue K, Noh, Dong-Young, Matsuo, Keitaro, Ito, Hidemi, Iwata, Hiroji, Yatabe, Yasushi, Guénel, Pascal, Truong, Thérèse, Menegaux, Florence, Sanchez, Marie, Burwinkel, Barbara, Marme, Frederik, Schneeweiss, Andreas, Sohn, Christof, Wu, Anna H, Tseng, Chiu-chen, Van Den Berg, David, Stram, Daniel O, Benitez, Javier, Pilar Zamora, M, Perez, Jose Ignacio Arias, Menéndez, Primitiva, Shu, Xiao-Ou, Lu, Wei, Gao, Yu-Tang, Cai, Qiuyin, Cox, Angela, Cross, Simon S, Reed, Malcolm WR, Andrulis, Irene L, Knight, Julia A, Glendon, Gord, Tchatchou, Sandrine, Sawyer, Elinor J, Tomlinson, Ian, Kerin, Michael J, Miller, Nicola, Haiman, Christopher A, Henderson, Brian E, Schumacher, Fredrick, Le Marchand, Loic, Lindblom, Annika, Margolin, Sara, and Teo, Soo Hwang

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Cancer
Abstract

This corrects the article DOI: 10.1038/ncomms5999.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results